The Utility of TH-302 in Sarcoma

Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses the cytotoxic chemotherapy TH-302.

Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses the cytotoxic chemotherapy TH-302.

Clinical Pearls:

  • TH-302 is similar to ifosfamide but is a hypoxia-induced agent
  • TH-302 targets the large areas of hypoxia found in sarcomas that chemotherapy cannot reach
  • A randomized phase III study of Adriamycin (doxorubicin) versus Adriamycin plus TH-302 is undergoing accrual
  • The initial phase II data is promising with good progression-free survival data